ADIAL PHARMACEUTICALS, INC.
Data quality: 83%
ADIL
Nasdaq
Manufacturing
Chemicals
$1.57
▲
$0.01
(0.64%)
Mkt Cap: 2.23 M
Price
$1.56
Mkt Cap
2.23 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—
Quick Summary
Key Takeaways
Negative free cash flow of -6.49 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-158.03%
Below sector avg (-53.41%)
ROIC-122.06%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio4.34
Interest CoverageN/A
Valuation
PE (TTM)
-0.28
Above sector avg (-1.48)
P/B Ratio0.49
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.3 | -1.5 |
| P/B | 0.5 | 1.6 |
| ROE % | -158.0 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -7.98 M |
| ROE | -158.03% | ROA | -128.03% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -6.49 M |
| ROIC | -122.06% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 4.34 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 3.86 M | Tangible Book Value | 4.50 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.28 | Forward P/E | N/A |
| P/B Ratio | 0.49 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -291.46% | ||
| Market Cap | 2.23 M | Enterprise Value | -2.38 M |
| Per Share | |||
| EPS (Diluted TTM) | -11.93 | Revenue / Share | N/A |
| FCF / Share | -4.55 | OCF / Share | -4.55 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 81.39% |
| SBC-Adj. FCF | -7.43 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -7.98 M | -13.20 M | -5.12 M | -12.73 M | -19.42 M |
| EPS (Diluted) | -11.93 | -2.72 | -3.60 | -0.51 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -7.80 M | -8.28 M | -6.89 M | -13.32 M | -19.29 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 2.62 M | 3.23 M | 1.27 M | 4.18 M | 8.40 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Income Tax | — | — | — | -502.0 | -94,077.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 6.67 M | 5.04 M | 4.74 M | 5.73 M | 7.47 M |
| Total Liabilities | 1.40 M | 975,858.0 | 653,076.0 | 2.46 M | 3.97 M |
| Shareholders' Equity | 5.28 M | 4.07 M | 4.08 M | 3.28 M | 3.51 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 5.88 M | 3.75 M | 2.83 M | 4.00 M | 6.06 M |
| Current Assets | 6.18 M | 4.06 M | 3.20 M | 4.78 M | 6.46 M |
| Current Liabilities | 1.40 M | 975,858.0 | 653,076.0 | 1.79 M | 2.72 M |
{"event":"ticker_viewed","properties":{"ticker":"ADIL","listing_kind":"stock","pathname":"/stocks/adil","exchange":"Nasdaq","country":"US"}}